NCT00169975

Brief Summary

A magnetocardiograph (MCG) is a device capable of recording of magnetic fields arising from the electrical activity of the heart with traces similar to an electrocardiogram (ECG). This system was developed as a noninvasive, non-contact diagnostics of obstructive coronary artery disease (CAD), and especially of lack of oxygen in the heart as in a heart attack. The overall objective of this study is to demonstrate the efficacy of this MCG device for the detection and diagnosis of lack of oxygen of the heart in patients with chest pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
137

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2004

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2004

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

September 12, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 15, 2005

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
Last Updated

July 18, 2011

Status Verified

July 1, 2011

Enrollment Period

3.5 years

First QC Date

September 12, 2005

Last Update Submit

July 15, 2011

Conditions

Outcome Measures

Primary Outcomes (2)

  • 1. Determine the discriminatory ability of the scores derived from the MCG evaluation to discriminate between patients with versus without a clinical diagnosis of ACS at discharge.

    1 year

  • 2. Compare the discriminatory ability of scores derived from the MCG, the troponin level, and the ECG results, separately or in combination, to discriminate between patients with without a diagnosis of ACS at discharge.

    1 year

Secondary Outcomes (1)

  • 1. Evaluate the sensitivity of the MCG to detect an ultimate diagnosis of ACS, MI, CHF, or death at 1 month, 6 months, and 1 year following discharge.

    1 year

Interventions

MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

\*ACC/AHA Guidelines for Unstable Angina: High Risk (≥1 of the following) History * Accelerating tempo of ischemic symptoms in the last 48 hrs Pain * Prolonged, ongoing (\>20 min) rest pain (resistant to treatment) Clinical findings * Pulmonary edema * New / ↑ MR murmur * S3 or new/ ↑ rales * Hypotension, brady -/tachycardia - Age\>75y ECG * Angina at rest with transient ST changes \>0.05 mV * New (L)BBB * Sustained VT Cardiac Markers * Markedly elevated troponin Patients classified as having high-risk unstable angina at presentation in the ED will be approached for enrollment in the study.

You may qualify if:

  • Patients classified as having High Risk Unstable Angina according to the ACCIAHA guidelines.
  • Age ≥ 18 years.

You may not qualify if:

  • Hemodynamically unstable patients.
  • Patients who just prior to or just after admission exhibit tachycardia with heart rates exceeding 150 bpm.
  • Patients with third degree AV Block.
  • Patients with pacemakers or internal cardiac defibrillators.
  • Patients who cannot lie in a supine position for the MCG examination.
  • Patients who refuse entry into the registry

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Myocardial Ischemia

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Peter A. Smars, M.D. EM

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 15, 2005

Study Start

August 1, 2004

Primary Completion

February 1, 2008

Study Completion

February 1, 2008

Last Updated

July 18, 2011

Record last verified: 2011-07

Locations